Sanofi Expands India Operations, Creates 2,000 New Jobs in Hyderabad

Sanofi, a French pharmaceutical giant, will increase its long-term presence in India by adding more than 4,500 jobs to its workforce at its global capabilities center (GCC) in Hyderabad. There are more than 2,600 people working at the centre right now. A "multi-hundred-million" investment will fund the expansion, according to the corporation, though it did not reveal the actual amount or a date for the hiring. This action expands upon Sanofi's previous pledge. A strategic shift towards developing high-value operations in the country was signalled in 2024 when the business announced plans to invest 400 million euros (approximately $474.6 million) in its India GCC by the end of the decade.

Details of Sanofi's Expansion

Sanofi Healthcare India announced in a statement that the new positions will cover a wide range of areas. These areas include commercial skills, corporate activities, medical affairs, data analytics, data innovation and artificial intelligence, and research and development. The growth of Sanofi is part of a larger trend of increased investment from global corporations in the GCC ecosystem in India.

The original purpose of these centres has changed; now they serve as nerve centres for digital transformation, operations, finance, and research and development. According to Anarock, a realty firm, there are over 1,700 GCCs in India, employing over 1.9 million people. With a compound yearly growth rate of around 10% and a possible number of centres topping 2,400, the firm predicts the industry may reach $105–110 billion by 2030.

Hyderabad Emerging as Hub for Life Science’s Players

Many multinational corporations in the technology and life sciences have set up shop in Hyderabad in recent years. An annual BioAsia conference is scheduled to take place in the city on February 17 and 18. During the conference, executives from major pharmaceutical companies such as Sanofi, Novo Nordisk, Merck, and Eli Lilly will be there to talk about expanding research and the potential prospects for India's pharmaceutical industry.

As an integral part of Sanofi's worldwide operations strategy, the Hyderabad centre supports innovation, digital capabilities, and enterprise services. Both as a manufacturing base and a hub for advanced research and technological skills, India is gaining prominence, and this scale-up is a prime example of that. The growing GCC ecosystem in India is set to play a pivotal role in the long-term expansion plans of multinational pharmaceutical corporations as they engage in digital capabilities and rebalance their supply chains.